Colchicine fails to improve knee pain, function, or size of synovial effusions with painful knee osteoarthritis (OA), ...

For patients with immunoglobulin G (IgG)4-related disease, inebilizumab reduces the risk for flares and increases the ...

A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active ...

NKTR-422 demonstrated inflammation resolution and tissue repair in multiple preclinical models of chronic inflammatory conditions - SAN FRANCISCO, Nov. 18, 2024 ...

Aurinia Pharmaceuticals Inc. (Aurinia or the Company) commends the American College of Rheumatology (ACR) for their 2024 evidence-based guidelines for the screening, treatment, and management of lupus ...

Long-term treatment with anifrolumab significantly reduced the rate of organ damage compared with SOC among patients with SLE ...

More than half the women in the treat-to-target group conceived within 3 months vs a median of 6.5 months for those in the ...

Most patients with rheumatoid arthritis or spondyloarthritis had significant antibody responses to COVID vaccine boosters, whether or not their immunomodulatory medications were held.

Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it ...

TNX-102 SL, a sublingual cyclobenzaprine HCl formulation, is safe and effective for treating fibromyalgia symptoms, according to study results presented at the American College of Rheumatology (ACR) ...

Initial Clinical Data from Phase 1 Autoimmunity Study of FT819 1XX CAR T-cell Product Candidate to be Presented in 4Q24; ...

The results were shared during an oral, late-breaker presentation at ACR Convergence 2024 ... of Lupus Low Disease Activity State and prevention of severe BILAG flares: 17.1% more participants ...